Home › Interpace Diagnostics Wins NY State Approval for Thyroid Cancer Testing Service

Interpace Diagnostics Wins NY State Approval for Thyroid Cancer Testing Service

Nov 16, 2017

NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that it has received approval from the New York State Department of Health (NYSDOH) for its TERT test offering, which is designed to detect a molecular biomarker of thyroid cancer aggressiveness.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Dec
03
Featured Webinar

Application of a Novel ISH Approach to Elucidate Splice Variants in Schizophrenia

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

What's Popular?

In Molecular Diagnostics

  1. ASHG: Dutch Nationwide NIPT Implementation Study Sees 42 Percent Uptake After First Year

  2. NeoGenomics to Acquire Genoptix for Cash, Stocks

  3. Singlera Genomics Presents Data on Cell-Free DNA Methylation Test for Early Cancer Detection

    Premium

  4. Thermo Fisher Scientific Gets CE-IVD Mark for NGS Cancer Test

  5. MRC Holland Gets CE-IVD Mark for Spinal Muscular Atrophy Assay

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.